Despite conventional treatment approaches, such as chemotherapy and radiation therapy, lymphoma persists in many patients. Therefore, the treatment for relapsed lymphoma remains challenging. The purpose of this study is to evaluate the safety and effectiveness of BKM120 in patients with diffuse large B-cell lymphoma, mantle cell lymphoma, or follicular lymphoma that has persisted or returned despite prior therapy.
BKM120 is an investigational drug designed to inhibit cancer growth by blocking PI3 kinase (PI3K), an enzyme which drives the growth and survival of some types of cancer, including hematologic cancers such as lymphoma. BKM120 is a pill that is taken orally (by mouth).